A review of cancer immunotherapy toxicity

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities

(2019) Filipe Martins et al.   LANCET ONCOLOGY

Hematologic Complications of Immune Checkpoint Inhibitors

(2019) Elizabeth J. Davis et al.   ONCOLOGIST

A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors

(2019) Jeroen de Filette et al.   HORMONE AND METABOLIC RESEARCH

Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy

(2019) Karen Bitton et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Early Administration of Tocilizumab (Toci) for the Prevention of Grade 4 Cytokine Release Syndrome (CRS) after CD19-directed CAR T-cell Therapy (CTL019)

(2019) S. Kadauke et al.   CYTOTHERAPY

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

(2019) Yucai Wang et al.   JAMA Oncology

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

(2019) Fiamma Berner et al.   JAMA Oncology

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

(2019) Hamzah Abu-Sbeih et al.   Journal for ImmunoTherapy of Cancer

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

(2019) Douglas B. Johnson et al.   Journal for ImmunoTherapy of Cancer

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

(2019) Douglas B. Johnson et al.   NATURE MEDICINE

Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis

(2019) Joe-Elie Salem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

(2019) Audrey Simonaggio et al.   JAMA Oncology

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2018) J B A G Haanen et al.   ANNALS OF ONCOLOGY

High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma

(2018) Alexander T. Faje et al.   CANCER

Multimodality imaging of endocrine immune related adverse events: a primer for radiologists

(2018) Francesco Alessandrino et al.   CLINICAL IMAGING

Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis

(2018) Yinghong Wang et al.   INFLAMMATORY BOWEL DISEASES

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

(2018) Xiaolei Li et al.   Journal of Hematology & Oncology

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors

(2018) Eleonora De Martin et al.   JOURNAL OF HEPATOLOGY

Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study

(2018) Charles Kyung Min Lee et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity

(2018) John A. Thompson   Journal of the National Comprehensive Cancer Network

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

(2018) Javid J Moslehi et al.   LANCET

Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents

(2018) Daniel L. Suzman et al.   LIVER INTERNATIONAL

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome

(2018) Robert Q. Le et al.   ONCOLOGIST

Immune Checkpoint Inhibitor‐Associated Myocarditis

(2018) Sarju Ganatra et al.   ONCOLOGIST

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen

(2018) Laura C. Cappelli et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

CAR-T cells: the long and winding road to solid tumors

(2018) Maria Michela D’Aloia et al.   Cell Death & Disease

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

(2018) Bianca D. Santomasso et al.   Cancer Discovery

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

(2018) Alexander N. Shoushtari et al.   JAMA Oncology

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens

(2018) Romualdo Barroso-Sousa et al.   JAMA Oncology

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson

(2018) Yinghong Wang et al.   Journal for ImmunoTherapy of Cancer

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy

(2018) Noelle Frey et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

(2018) Jennifer N. Brudno et al.   BLOOD REVIEWS

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

(2018) Yinghong Wang et al.   NATURE MEDICINE

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

(2018) Nicolas Delanoy et al.   Lancet Haematology

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

(2018) Daniel H Johnson et al.   Journal for ImmunoTherapy of Cancer

Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

(2017) S. Cuzzubbo et al.   EUROPEAN JOURNAL OF CANCER

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib

(2017) Cameron J. Turtle et al.   JOURNAL OF CLINICAL ONCOLOGY

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

(2017) Mario Sznol et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

(2017) Hans J. Hammers et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

(2017) Paolo A Ascierto et al.   LANCET ONCOLOGY

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies

(2017) David J. Byun et al.   Nature Reviews Endocrinology

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis

(2017) James Larkin et al.   ONCOLOGIST

Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature

(2017) Laura C. Cappelli et al.   ARTHRITIS CARE & RESEARCH

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

(2017) Juliane Gust et al.   Cancer Discovery

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy

(2017) Hyunju Lee et al.   Cancer Immunology Research

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

(2017) Vivek Kumar et al.   Frontiers in Pharmacology

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade

(2017) Chipman RG Stroud et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Nivolumab induced myxedema crisis

(2017) Uqba Khan et al.   Journal for ImmunoTherapy of Cancer

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients

(2016) Anushree C. Shirali et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade

(2016) Patrizio Caturegli et al.   AMERICAN JOURNAL OF PATHOLOGY

Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma

(2016) H. Vallet et al.   ANNALS OF ONCOLOGY

Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer

(2016) J.C. Osorio et al.   ANNALS OF ONCOLOGY

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

(2016) A. M. Menzies et al.   ANNALS OF ONCOLOGY

Ocular and orbital side-effects of checkpoint inhibitors

(2016) Joëlle Antoun et al.   CURRENT OPINION IN ONCOLOGY

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

(2016) V.R. Belum et al.   EUROPEAN JOURNAL OF CANCER

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Diverse types of dermatologic toxicities from immune checkpoint blockade therapy

(2016) Jonathan L. Curry et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

(2016) Frank B. Cortazar et al.   KIDNEY INTERNATIONAL

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

(2016) Cameron J. Turtle et al.   Science Translational Medicine

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

(2016) Krista Dubin et al.   Nature Communications

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

(2016) Camille Hua et al.   JAMA Dermatology

Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer

(2016) Mizuki Nishino et al.   JAMA Oncology

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Systematic review: colitis associated with anti-CTLA-4 therapy

(2015) A. Gupta et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

(2015) Anne Bertrand et al.   BMC Medicine

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

(2015) Hansje-Eva Teulings et al.   JOURNAL OF CLINICAL ONCOLOGY

Toxicities of Immunotherapy for the Practitioner

(2015) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Immune evasion in cancer: Mechanistic basis and therapeutic strategies

(2015) Dass S. Vinay et al.   SEMINARS IN CANCER BIOLOGY

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma

(2015) Ahmad A. Tarhini et al.   Journal for ImmunoTherapy of Cancer

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study

(2014) L. Min et al.   CLINICAL CANCER RESEARCH

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

(2014) Mabel Ryder et al.   ENDOCRINE-RELATED CANCER

Designing Therapeutic Clinical Trials for Older and Frail Adults With Cancer: U13 Conference Recommendations

(2014) Arti Hurria et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

(2014) B. Liao et al.   NEURO-ONCOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

(2014) S. Iwama et al.   Science Translational Medicine

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

(2013) Jeffrey S. Weber et al.   CANCER

Cellular and molecular mechanisms in cancer immune escape: a comprehensive review

(2013) Alka Bhatia et al.   Expert Review of Clinical Immunology

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

(2011) Katarzyna D. Chmiel et al.   JOURNAL OF CLINICAL ONCOLOGY

Th17 Cells Induce Colitis and Promote Th1 Cell Responses through IL-17 Induction of Innate IL-12 and IL-23 Production

(2011) T. Feng et al.   JOURNAL OF IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

(2010) C. Krieg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

(2009) J. Weber et al.   CLINICAL CANCER RESEARCH